title: Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study.
abstract: Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.
authors.affiliation: Departments of Gastroenterology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil. lemazzoleni@yahoo.com.br
authors.forename: Luiz E
authors.initials: LE
authors.lastname: Mazzoleni
authors.forename: Guilherme B
authors.initials: GB
authors.lastname: Sander
authors.forename: Eduardo A
authors.initials: EA
authors.lastname: Ott
authors.forename: Sérgio G S
authors.initials: SG
authors.lastname: Barros
authors.forename: Carlos F
authors.initials: CF
authors.lastname: Francesconi
authors.forename: Carisi A
authors.initials: CA
authors.lastname: Polanczyk
authors.forename: André C
authors.initials: AC
authors.lastname: Wortmann
authors.forename: Alexandro L
authors.initials: AL
authors.lastname: Theil
authors.forename: Leandro G
authors.initials: LG
authors.lastname: Fritscher
authors.forename: Luis F
authors.initials: LF
authors.lastname: Rivero
authors.forename: André
authors.initials: A
authors.lastname: Cartell
authors.forename: Maria I A
authors.initials: MI
authors.lastname: Edelweiss
authors.forename: Diego M
authors.initials: DM
authors.lastname: Uchôa
authors.forename: João C
authors.initials: JC
authors.lastname: Prolla
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001706:Biopsy; D001938:Brazil / Q000453:epidemiology; D017291:Clarithromycin / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology; D005756:Gastritis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015995:Prevalence; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000890:Anti-Infective Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole